Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00134134
Status:
COMPLETED
Last Update Posted:
2006-09-11
First Post:
2005-08-23
Brief Title:
Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa
Sponsor:
NYU Langone Health
Organization:
NYU Langone Health
Study Overview
Official Title:
An Open-Label Assessment of the Efficacy Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa
Status:
COMPLETED
Status Verified Date:
2006-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the effectiveness and safety of efalizumab in treating hydradenitis suppurativa and to evaluate the duration of the benefit seen in people who respond to treatment with efalizumab after the medication is stopped
Detailed Description:
The primary objective of this study is to assess the efficacy of subcutaneously administered efalizumab in the treatment of refractory severe hydradenitis suppurativa The secondary objectives of this study are to assess the ability to re-establish disease control after discontinuation of drug and allowance for relapse of disease as well as to assess the safety of subcutaneously administered efalizumab in the treatment of refractory severe hydradenitis suppurativa
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None